Phone: 49 (0)6027 40 900-51
curasan AG is publicly traded (ISIN: DE 000 549 453 8) and is one of the leading firms in the field of bone and tissue regeneration. In addition to the synthetic Cerasorb┬« bone regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to bring further medical products to market readiness and to market them via well-positioned contractual partners in various submarkets.
curasan AG created a new post in relation to the active expansion of its European sales network in the fields of Orthopaedics and trauma surgery. Mr. Lee McCann, BSc Business Administration, will be operating as the organisation's International Sales Director for Orthobiologics.
curasan AG, which is listed in the General Standard of the German Stock Exchange has received FDA certification and, therefore, marketing authorization throughout the USA of the synthetic bone replacement material Osbone« Dental which already has been authorized in the EU as Osbone«.
curasan AG, listed in the General Standard of the German Stock Exchange has signed an agreement with Stryker S.A., Montreux, Switzerland, to sell and market bone replacement and regeneration materials for different orthopedic indications.
curasan Inc., the north American subsidiary of exchange listed curasan AG, Germany has signed an exclusive supply agreement with TransCorp Spine Inc., Michigan, USA, for Cerasorb« Ortho block forms used to repair vertebral bone channels created during surgeries to decompress neural tissue in the spine.
Supporting wound healing and tissue regeneration through the extraction of autologous platelet-mediator-concentrate (PMC) - high patient compatibility using autologous blood - No need for centrifuges and external laboratories